−173.84 MCHF
743.70 MCHF
146.24 M
About EVOTEC SE
Sector
CEO
Mario Eugenio Cosimino Polywka
Headquarters
Hamburg
Website
Employees (FY)
4.95 K
Founded
1998
ISIN
DE0005664809
FIGI
BBG006TLPSX3
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Big pullback and off to new highs?This one had an insane run the last couple month. Here comes the first bigger pullback this year. Is it a sign of weakness? I dont think so. I believe, it was just profits taken.
So I will ride the trend again, and follow the price to where it has never been (with this stock).
Wait how Price reac
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EVT is 12.95 CHF — it has decreased by 4.58% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange EVOTEC SE stocks are traded under the ticker EVT.
EVOTEC SE is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for EVOTEC SE has a max estimate of 37.65 CHF and a min estimate of 14.93 CHF.
EVT earnings for the last quarter are −0.12 CHF whereas the estimation was −0.11 CHF which accounts for −9.09% surprise. Estimated earnings for the next quarter are −0.06 CHF. See more details about EVOTEC SE earnings.
EVOTEC SE revenue for the last quarter amounts to 166.32 M CHF despite the estimated figure of 178.44 M CHF. In the next quarter revenue is expected to reach 170.56 M CHF.
Yes, you can track EVOTEC SE financials in yearly and quarterly reports right on TradingView.
Like other stocks, EVT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EVOTEC SE stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 4.95 K employees. See our rating of the largest employees — is EVOTEC SE on this list?